Incremental healthcare resource utilization and costs in US patients with Cushing’s disease compared with diabetes mellitus and population controls

Pituitary

Volumn 18, Issue 6, 2015, Pages 796-802

  Broder, Michael S ^a   Neary, Maureen P ^b   Chang, Eunice ^a   Ludlam, William H ^b  

^a PARTNERSHIP FOR HEALTH ANALYTIC RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cost analysis; Costs; Cushing disease; Cushing syndrome; Diabetes mellitus; Utilization

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CUSHING DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES; YOUNG ADULT; ECONOMICS; FACTUAL DATABASE; POPULATION DYNAMICS; STATISTICS AND NUMERICAL DATA;

ADULT; DATABASES, FACTUAL; DIABETES MELLITUS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; PITUITARY ACTH HYPERSECRETION; POPULATION CONTROL;

EID: 84945484435     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-015-0654-5     Document Type: Article

References (26)

1. Colao A, Boscaro M, Ferone D, Casanueva FF (2014) Managing Cushing’s disease: the state of the art. Endocrine 47(1):9–20
2. Broder MS, Neary MP, Chang E, Cherepanov D, Ludlam WH (2014) Incidence of Cushing’s syndrome and Cushing’s disease in commercially-insured patients <65 years old in the United States. Pituitary [Epub ahead of print]
3. Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing’s syndrome. Lancet 367:1605–1617
4. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, Romijn JA (2007) Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92:976–981
5. Broder MS, Neary MP, Chang E, Ludlam WH, Cherepanov D (2013) Annual economic burden associated with Cushing’s disease in the United States. Presented at: ENDO 2013, 17 June 2013, San Francisco, CA
6. Swearingen B, Wu N, Chen SY, Pulgar S, Biller BM (2011) Health care resource use and costs among patients with Cushing disease. Endocr Pract 17:681–690
7. Burton T, Le Nestour E, Neary M, Ludlam WH (2014) Economic burden of Cushing’s disease in a large US managed care health care plan. Presented at: ENDO 2014, 21–24 June 2014, Chicago, IL
8. Patil CG, Lad SP, Harsh GR, Laws ER Jr, Boakye M (2007) National trends, complications, and outcomes following transsphenoidal surgery for Cushing’s disease from 1993 to 2002. Neurosurg Focus 23(3):E7
9. th International Pituitary Congress, 12–14 June 2013, San Francisco, CA
10. Bureau of Labor Statistics. Consumer Price Index: Measuring Price Change for Medical Care in the CPI. http://www.bls.gov/cpi/cpifact4.htm. Last updated 12 April 2010. Last Accessed 29 April 2014
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
12. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619
13. Hwang W, Weller W, Ireys H, Anderson G (2001) Out-of-pocket medical spending for care of chronic conditions. Health Aff 20:267–278
14. American Diabetes Association (2013) Economic costs of diabetes in the US in 2012. Diabetes Care 36:1033–1046
15. Brilleman SL, Purdy S, Salisbury C, Windmeijer F, Gravelle H, Hollinghurst S (2013) Implications of comorbidity for primary care costs in the UK: a retrospective observational study. Br J Gen Pract 63:e274–e282
16. Meyers JL, Parasuraman S, Bell KF, Graham JP, Candrilli SD (2014) The high-cost, type 2 diabetes mellitus patient: an analysis of managed care administrative data. Arch Public Health 72:6
17. O’Shea M, Teeling M, Bennett K (2013) The prevalence and ingredient cost of chronic comorbidity in the Irish elderly population with medication treated type 2 diabetes: a retrospective cross-sectional study using a national pharmacy claims database. BMC Health Serv Res 13:23
18. American Diabetes Association (2014) Standards of medical care in diabetes–2014. Diabetes Care 37(Suppl. 1):S14–S80
19. Buchfelder M, Schlaffer S (2010) Pituitary surgery for Cushing’s disease. Neuroendocrinology 92(Suppl 1):102–106
20. Loh-Trivedi M (2014) Perioperative management of the diabetic patient. Medscape from WebMD. http://emedicine.medscape.com/article/284451-overview. Last updated June 10, 2013. Accessed 16 Sept 2014
21. Patel DA, Maldonado M, Stephens JM, Pulgar S, Swearingen B (2011) Cost of second line non-pharmacologic interventions and their related complications in Cushing’s disease: A literature-based economic analysis. Presented at: 12th International Pituitary Congress, June 1–3, 2011, Boston, MA
22. Frisch A, Chandra P, Smiley D, Peng L, Rizzo M, Gatcliffe C, Hudson M, Mendoza J, Johnson R, Lin E, Umpierrez GE (2010) Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care 33:1783–1788
23. Aron DC (2010) Cushing’s syndrome: why is diagnosis so difficult? Rev Endocr Metab Disord 11:105–116
24. Bertagna X, Guignat L, Groussin L, Bertherat J (2009) Cushing’s disease. Best Pract Res Clin Endocrinol Metab 23:607–623
25. Tritos NA, Biller BM, Swearingen B (2011) Management of Cushing disease. Nat Rev Endocrinol 7:279–289
26. Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167:311–326